BRAF and metastatic melanoma: Furthermore, vemurafenib, the first BRAF inhibitor approved by the FDA in 2011 for metastatic melanoma with the BRAFV600E mutation, has demonstrated an increase in OS compared with dacarbazine in a phase III (BRIM-3) trial [63,64,65,66].